Shrey Modi1, Devika Kir1, Bhuwan Giri1, Kaustav Majumder1, Nivedita Arora1, Vikas Dudeja1, Sulagna Banerjee1, Ashok K Saluja2. 1. Division of Basic and Translational Research, Department of Surgery, University of Minnesota, 420 Delaware Street SE, MMC195, Minneapolis, MN, 55455, USA. 2. Division of Basic and Translational Research, Department of Surgery, University of Minnesota, 420 Delaware Street SE, MMC195, Minneapolis, MN, 55455, USA. asaluja@umn.edu.
Abstract
INTRODUCTION: Oxaliplatin is part of pancreatic cancer therapy in the FOLFIRINOX or GEMOX/XELOX regimen. DNA damage repair is one of the factors responsible for oxaliplatin resistance that eventually develops in this cancer. Triptolide/Minnelide has been shown to be effective against pancreatic cancer in preclinical trials. In this study, we evaluated the efficacy of combination of triptolide and oxaliplatin against pancreatic cancer. METHODS: Highly aggressive pancreatic cancer cells (MIA PaCa-2 and PANC-1) were treated with oxaliplatin (0-10 μM), low-dose triptolide (50 nM), or a combination of both for 24-48 h. Cell viability, apoptosis, and DNA damage were evaluated by appropriate methods. Nucleotide excision repair pathway components were quantitated using qPCR and Western blot. Combination of low doses of Minnelide and oxaliplatin was tested in an orthotopic murine model of pancreatic cancer. RESULTS: Proliferation of pancreatic cancer cells was markedly inhibited by combination treatment. Triptolide potentiated apoptotic cell death induced by oxaliplatin and sensitized cancer cells towards oxaliplatin-induced DNA damage by suppressing the oxaliplatin-induced DNA damage repair pathway. Combination of low doses of Minnelide and oxaliplatin inhibited tumor progression by inducing significant apoptotic cell death in these tumors. CONCLUSIONS: Combination of low doses of Minnelide and oxaliplatin has immense potential to emerge as a novel therapeutic strategy against pancreatic cancer.
INTRODUCTION:Oxaliplatin is part of pancreatic cancer therapy in the FOLFIRINOX or GEMOX/XELOX regimen. DNA damage repair is one of the factors responsible for oxaliplatin resistance that eventually develops in this cancer. Triptolide/Minnelide has been shown to be effective against pancreatic cancer in preclinical trials. In this study, we evaluated the efficacy of combination of triptolide and oxaliplatin against pancreatic cancer. METHODS: Highly aggressive pancreatic cancer cells (MIA PaCa-2 and PANC-1) were treated with oxaliplatin (0-10 μM), low-dose triptolide (50 nM), or a combination of both for 24-48 h. Cell viability, apoptosis, and DNA damage were evaluated by appropriate methods. Nucleotide excision repair pathway components were quantitated using qPCR and Western blot. Combination of low doses of Minnelide and oxaliplatin was tested in an orthotopic murine model of pancreatic cancer. RESULTS: Proliferation of pancreatic cancer cells was markedly inhibited by combination treatment. Triptolide potentiated apoptotic cell death induced by oxaliplatin and sensitized cancer cells towards oxaliplatin-induced DNA damage by suppressing the oxaliplatin-induced DNA damage repair pathway. Combination of low doses of Minnelide and oxaliplatin inhibited tumor progression by inducing significant apoptotic cell death in these tumors. CONCLUSIONS: Combination of low doses of Minnelide and oxaliplatin has immense potential to emerge as a novel therapeutic strategy against pancreatic cancer.
Entities:
Keywords:
DNA damage pancreatic cancer; Minnelide; NER; Oxaliplatin; Triptolide
Authors: Thierry Conroy; Françoise Desseigne; Marc Ychou; Olivier Bouché; Rosine Guimbaud; Yves Bécouarn; Antoine Adenis; Jean-Luc Raoul; Sophie Gourgou-Bourgade; Christelle de la Fouchardière; Jaafar Bennouna; Jean-Baptiste Bachet; Faiza Khemissa-Akouz; Denis Péré-Vergé; Catherine Delbaldo; Eric Assenat; Bruno Chauffert; Pierre Michel; Christine Montoto-Grillot; Michel Ducreux Journal: N Engl J Med Date: 2011-05-12 Impact factor: 91.245
Authors: Daniel Borja-Cacho; Yumi Yokoyama; Rohit K Chugh; Nameeta R Mujumdar; Vikas Dudeja; Kimberly A Clawson; Rajinder K Dawra; Ashok K Saluja; Selwyn M Vickers Journal: J Gastrointest Surg Date: 2009-12-16 Impact factor: 3.452
Authors: Pawan Noel; Shaimaa Hussein; Serina Ng; Corina E Antal; Wei Lin; Emily Rodela; Priscilla Delgado; Sanna Naveed; Michael Downes; Yin Lin; Ronald M Evans; Daniel D Von Hoff; Haiyong Han Journal: Oncogenesis Date: 2020-11-09 Impact factor: 7.485
Authors: Vivek Ramakrishnan; Christopher de Haydu; Peter Wilkinson; Urvashi Hooda; Bhuwan Giri; Janneth M Oleas; Veronica Rive; Sabita Roy; Vikas Dudeja; Brian Slomovitch; Ashok Saluja; Sundaram Ramakrishnan Journal: Am J Cancer Res Date: 2021-05-15 Impact factor: 6.166